



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C07H 17/08, A61K 31/70</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/51616</b> <b>(43) International Publication Date:</b> 14 October 1999 (14.10.99)
<b>(21) International Application Number:</b> PCT/HR99/00004 <b>(22) International Filing Date:</b> 2 April 1999 (02.04.99) <b>(30) Priority Data:</b> P980189A      6 April 1998 (06.04.98)      HR <b>(71) Applicant (for all designated States except US):</b> PLIVA, FARMACEUTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA, DIONIČKO DRUŠTVO [HR/HR]; Ulica grada Vukovara 49, HR-10000 Zagreb (HR). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LAZAREVSKI, Gorjana [HR/HR]; Barutanski jarak 18, HR-10000 Zagreb (HR). KOBREHEL, Gabrijela [HR/HR]; Trg Ivana Kukuljevića 3, HR-10000 Zagreb (HR). KELNERIĆ, Željko [HR/HR]; Mašićeva 12, HR-10000 Zagreb (HR). <b>(74) Common Representative:</b> PLIVA d.d.; Pravni Poslovi, Vesna Vasiljevic, Ulica grada Vukovara 49, HR-10000 Zagreb (HR).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> 15-MEMBERED LACTAMS KETOLIDES WITH ANTIBACTERIAL ACTIVITY  <b>(57) Abstract</b> <p>The present invention relates to the new 15-membered ketoazalides from the class of 6-O-methyl-8a-aza-8a-homo- and 6-O-methyl-9a-aza-9a-homoerythromycin A with general formula (I), wherein A represents NH group and B at the same time represents C=O group, or A represents C=O group and B at the same time represents NH group, R<sup>1</sup> represents OH group, L-cladinosyl group of formula (II) or together with R<sup>2</sup> represents ketone, R<sup>2</sup> represents hydrogen or together with R<sup>1</sup> represents ketone, R<sup>3</sup> represents hydrogen or C<sub>1</sub>-C<sub>4</sub>alkanoyl group, to intermediates and a process for their preparation, to their pharmaceutically acceptable addition salts with inorganic or organic acids, to the process for the preparation of pharmaceutical compositions, as well as to the use of pharmaceutical compositions for treating bacterial infections.</p> <div style="text-align: center;"> <p>(I)</p> </div> <div style="text-align: center;"> <p>(II)</p> </div>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
ER	Estonia						

## 15-MEMBERED LACTAMS KETOLIDES WITH ANTIBACTERIAL ACTIVITY

*Technical Problem*

The present invention relates to new compounds of erythromycin A macrolide antibiotics class. Especially, it relates to new 15-membered ketoazalides of the class of 6-*O*-methyl-8a-aza-8a-homo- and 6-*O*-methyl-9a-aza-9a-homoerythromycin A, to intermediates and a process for their preparation, to their pharmaceutically acceptable addition salts with inorganic and organic acids, to a process for the preparation of pharmaceutical compositions as well as to the use of pharmaceutical compositions in the treatment of bacterial infections.

*Prior Art*

Erythromycin A is a macrolide antibiotic, whose structure is characterized by a 14-membered lactone ring having C-9 ketone and two sugars, L-cladinose and D-desosamine, which are glycosidically bound at C-3 and C-5 positions to the aglycone part of the molecule (McGuire: Antibiot. Chemother., 1952, 2: 281). For more than 40 years erythromycin A has been considered to be a safe and active antimicrobial agent for treating respiratory and genital infections caused by gram-positive bacteria of the strains like *Legionella*, *Mycoplasma*, *Chlamidia* and *Helicobacter*. The observed changes in bioavailability after the application of oral preparations, gastric intolerance in many patients and the loss of activity in an acidic medium are the main disadvantages of the therapeutical use of erythromycin A. The spirocyclization of aglycone ring is successfully inhibited by the chemical transformation of C-9 ketone or of hydroxyl groups at C-6 and/or C-12 position. Thus e.g. by oximation of C-9 ketone of erythromycin A with hydroxylamine hydrochloride, Beckmann's rearrangement of the obtained 9(*E*)-oxime and reduction of the thus formed 6,9-imino ether (6-deoxy-9-deoxo-9a-aza-9a-homoerythromycin A 6,9-cyclic imino ether), there was obtained 9-deoxo-9a-aza-9a-homoerythromycin A, the first semisynthetic macrolide

having a 15-membered azalactone ring (Kobrehel G. et al., US Pat. 4,328,334, 5/1982). By reductive methylation of the newly introduced endocyclic 9a-amino group according to Eschweiler-Clark process, 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A (AZITHROMYCIN), a prototype of a new azalide antibiotics class was synthesized (Kobrehel G. et al., BE 892 357, 7/1982). In addition to the broad antimicrobial spectrum including gram-negative bacteria, azithromycin is also characterized by a long biological half-time, a specific transport mechanism to the site of application and a short therapy period. Azithromycin is able to penetrate and to accumulate within human phagocyte cells, which results in an improved action upon intracellular pathogenic microorganisms of the strains *Legionella*, *Chlamydia* and *Helicobacter*.

Further, it is known that C-6/C-12 spirocyclization of erythromycin A is also inhibited by *O*-methylation of C-6 hydroxyl group of aglycone ring (Watanabe Y. et al., US Pat. 4,331,803, 5/1982). By reaction of erythromycin A with benzyloxycarbonyl chloride followed by methylation of the obtained 2'-*O*,3'-*N*-bis(benzyloxycarbonyl)-derivative, elimination of the protecting groups and 3'-*N*-methylation, 6-*O*-methylerythromycin A (CLARITHROMYCIN) (Morimoto S. et al., J.Antibiotics 1984, 37, 187) is formed. If compared to erythromycin A, clarithromycin is considerably more stable in acidic medium and shows an increased *in vitro* activity against gram-positive bacterial strains (Kirst H.A. et al, Antimicrobial Agents and Chemother., 1989, 1419).

New investigations on 14-membered macrolides have led to a new type of macrolide antibiotics, namely ketolides, characterized by 3-keto group instead of neutral sugar L-cladinose, the latter being well-known for its instability even in a weakly acidic medium (Agouridas C. et al., EP 596802 A1, 5/1994, Le Martret O., FR 2697524 A1, 5/94). Ketolides exhibit significantly improved *in vitro* activity against MLS (macrolide, lincosamide and streptogramine B) induced by resistant organisms (Jamjian C., Antimicrob. Agents Chemother., 1997, 41, 485).


According to the known and established prior art, 15-membered ketoazalides from the class of 6-*O*-methyl-8a-aza-8a-homo- and 6-*O*-methyl-9a-aza-9a-homoerythromycin

A and their pharmaceutically acceptable addition salts with organic or inorganic acids, methods and intermediates for their preparation as well as methods for the preparation of pharmaceutical preparations and the use thereof have hitherto not been described.

The object of the present invention is represented by Beckmann's rearrangement of 9(*E*)- and 9(*Z*)-oxime of 6-*O*-methylerythromycin A, hydrolysis of cladinose in thus obtained 8a- and 9a-lactams, protection of hydroxyl groups in 2'-position of desosamine, oxidation of the 3-hydroxyl group and removal of protecting groups, whereby new, hitherto not described 15-membered ketoazalides from the class of 6-*O*-methyl-8a-aza-8a-homo- and 6-*O*-methyl-9a-aza-9a-homoerythromycin A are obtained.

#### *Technical Solution*


New 15-membered ketoazalides from the class of 6-*O*-methyl-8a-aza-8a-homo- and 6-*O*-methyl-9a-aza-9a-homoerythromycin A with the general formula (I)



wherein

A represents NH group and B at the same time represents C=O group, or  
A represents C=O group and B at the same time represents NH group,

$R^1$  represents OH group, L-cladinosyl group of the formula (II)



or together with  $R^2$  represents ketone,


$R^2$  represents hydrogen or together with  $R^1$  represents ketone,

$R^3$  represents hydrogen or  $C_1$ - $C_4$  alkanoyl group,

and their pharmaceutically acceptable addition salts with inorganic or organic acids are obtained as follows.


Step 1:

The first step of the invention includes oximation of C-9 ketone of 6-O-methylerythromycin A (clarithromycin) of the formula (III)



into the corresponding oxime. The conversion of ketone into oxime is a well-known reaction usually performed with hydroxylamine hydrochloride in the presence of


appropriate inorganic or organic bases in a suitable protic or aprotic solvent. Hydroxylamine hydrochloride is used in a 1 to 15-equimolar excess, preferably in a 10-equimolar excess with regard to clarithromycin. As suitable bases alkali hydroxides, carbonates, hydrogen carbonates and acetates are used whereas as solvents C<sub>1</sub>-C<sub>3</sub> alcohols are used. The preferred base is sodium carbonate or sodium acetate and the preferred solvent is methanol. In general, the reaction is performed at a temperature from 0 to 80°C, preferably at 65°C, within 2 hours to a few days, but mainly it is accomplished within 8 to 20 hours. The treatment is performed in the usual manner, e.g. by evaporation of the solvent under vacuum, addition of a mixture of water and organic solvent followed by extraction in an alkaline medium, preferably at pH 8.0-10.0. As solvents for the extraction of the product methylene chloride, chloroform, ethyl acetate, diethylether and toluene are used, with chloroform being the preferred one. The product is isolated by the separation of the organic layer and evaporation of the solvent, which yields a mixture of 6-*O*-methylethromycin A 9(*E*)- and 9(*Z*)-oxime of the formula (IV)




in a ratio of about 1:1. If necessary, the separation of the isomers is performed by chromatography on a silica gel column by using the system methylene chloride-methanol-ammonium hydroxide 90:9:1.5, which yields a chromatographically



homogeneous 6-*O*-methyl-erythromycin A 9(*E*)-oxime with R<sub>f</sub> 0.446 of the formula (IVa)




and chromatographically homogeneous 6-*O*-methylerythromycin A 9(*Z*)-oxime with R<sub>f</sub> 0.355 of the formula (IVb)






## Step 2:

Conversion of 6-*O*-methyl-erythromycin A 9(*E*)-oxime of formula (IVa) into 6-*O*-methyl-9a-aza-9a-homoerythromycin A of the general formula (I)



wherein A represents NH group, B at the same time represents C=O group, R<sup>1</sup> represents L-cladinosyl group of the formula (II)



R<sup>2</sup> and R<sup>3</sup> are the same and represent hydrogen, is performed by the reaction of Beckmann's rearrangement (see "Comprehensive Organic Chemistry", I.O. Sutherland (Ed.), Pergamon Press, New York, 1979, Vol. 2, 398-400 and 967-968). In general, Beckmann's rearrangement of ketoxime leads to carboxamide or, in the case of cyclic systems, to lactams. The rearrangement mechanism includes a preliminary conversion of oxime hydroxyl into a better leaving group, which in a second reaction step is cleaved off under a simultaneous migration of the carbon atom in the *anti*-position with regard to the leaving group. In an aqueous

medium as an intermediate a nitrilium ion is formed, which reacts with water yielding an appropriate amide.

The reaction of Beckmann's rearrangement is performed under acidic, neutral and basic conditions. Common acidic reagents catalyzing the rearrangement include conc. sulfuric acid, polyphosphoric acid, thionyl chloride, phosphoric pentachloride, sulfur dioxide and formic acid. Due to the sensibility of macrolide molecule in an acidic medium and especially due to the ease of cleavage of neutral sugar L-cladinose, these reagents are not suitable for the rearrangement of oxime of the formula (IVa) into 6-*O*-methyl-9a-aza-9a-homoerythromycin A of the general formula (I), wherein A, B, R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> have the above-mentioned meanings. Preferably, Beckmann's rearrangement of oxime (IVa) is performed by initial *O*-sulfonation of oxime hydroxyl with alkylsulfonyl halides, arylsulfonyl halides or arylsulfonyl anhydrides. Intermediate oxime sulfonate is isolated or, usually, the rearrangement into the desired product is performed *in situ*. Generally, sulfonation and rearrangement are performed in the presence of organic or inorganic bases.

The preferred sulfonation reagents catalyzing the rearrangement of oxime (IVa) include methanesulfonyl chloride, benzenesulfonyl chloride, 4-acetylamidosulfonyl chloride, *p*-toluenesulfonyl chloride, anhydrides of benzenesulfonic and *p*-toluenesulfonic acid. The reaction is performed in the presence of inorganic bases such as sodium hydrogen carbonate or potassium carbonate or in presence of organic bases such as pyridine, 4-dimethylaminopyridine, triethylamine and *N,N*-diisopropylamine. Suitable solvents include aqueous mixtures such as acetone-water mixture and dioxan-water mixture, and organic solvents such as methylene chloride, chloroform, ethyl acetate, diethyl ether, tetrahydrofuran, toluene, acetonitrile and pyridine. Generally, the reaction is performed by the use of 1-3 equimolar excess of the sulfonation reagent and with the same or greater equimolar amount of the base at a temperature from -20 to 50°C. Pyridine is often used as the solvent and as the base at the same time. Preferably, Beckmann's rearrangement of oxime (IVa) is performed in an acetone-water mixture with a double equimolar excess of *p*-toluenesulfochloride and sodium hydrogen carbonate. If necessary, the product is purified by chromatography on a

silica gel column by the use of the solvent system methylene chloride-methanol-ammonium hydroxide 90:9:1.5, yielding a chromatographically homogeneous 6-*O*-methyl-9a-aza-9a-homoerythromycin A.

Beckmann's rearrangement of 6-*O*-methylethromycin A 9(*Z*)-oxime of the formula (IVb) into 6-*O*-methyl-8a-aza-8a-homoerythromycin A of the general formula (I), wherein A represents C=O group, B at the same time represents NH group, R<sup>1</sup> represents L-cladinosyl group of the formula (II), and R<sup>2</sup> and R<sup>3</sup> are the same and represent hydrogen, is performed in analogous manner as with 9(*E*)-oxime (IVa).

Step 3:

6-*O*-methyl-9a-aza-9a-homoerythromycin A or 6-*O*-methyl-8a-aza-8a-homoerythromycin A of Step 2 of the general formula (I), wherein A, B, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the above-mentioned meanings, are subjected, if appropriate, to the action of strong acids, preferably 0.25-1.5 N hydrochloric acid, at room temperature within 10-30 hours, yielding 3-*O*-decladinosyl-3-oxy-derivatives of 6-*O*-methyl-9a-aza-9a-homoerythromycin A or 6-*O*-methyl-8a-aza-8a-homoerythromycin A of the general formula (I), wherein A represents NH group and B at the same time represents C=O group, or A represents C=O group and B at the same time represent NH group, R<sup>1</sup> represents OH group, and R<sup>2</sup> and R<sup>3</sup> are the same and represent hydrogen.

Step 4:

3-*O*-decladinosyl-3-oxy-6-*O*-methyl-9a-aza-9a-homoerythromycin A or 6-*O*-methyl-8a-aza-8a-homoerythromycin A of Step 3 of the general formula (I), wherein A, B, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the above-mentioned meanings, are subjected, if appropriate, to the reaction of selective acylation of hydroxyl group at 2'-position of desosamine. Acylation is performed by the use of anhydrides of carboxylic acids having up to 4 carbon atoms, preferably with acetic acid anhydride, in the presence of inorganic or organic bases in an inert organic solvent at a temperature from 0 to 30°C yielding 3-decladinosyl-3-oxy-6-*O*-methyl-9a-aza-9a-homoerythromycin A 2'-*O*-acetate or 3-decladinosyl-3-oxy-6-*O*-methyl-8a-aza-8a-homoerythromycin A 2'-*O*-acetate of the general formula (I), wherein A represents NH group and B at the same time represents

C=O group, or A represents C=O group and B at the same time represent NH group, R<sup>1</sup> represents OH group, R<sup>2</sup> is hydrogen and R<sup>3</sup> is acetyl. As appropriate bases sodium hydrogen carbonate, sodium carbonate, potassium carbonate, triethylamine, pyridine, tributylamine, preferably sodium hydrogen carbonate are used. As a suitable inert solvent methylene chloride, dichloro ethane, acetone, pyridine, ethyl acetate, tetrahydrofuran, preferably methylene chloride are used.

Step 5:

3-decladinosyl-3-oxy-6-*O*-methyl-9a-aza-9a-homoerythromycin A-2' *O*-acetate or 3-decladinosyl-3-oxy-6-*O*-methyl-8a-aza-8a-homoerythromycin A-2' *O*-acetate of Step 4 of the general formula (I), wherein A, B, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the above-mentioned meanings, are subjected, if appropriate, to an oxidation of the hydroxyl group at C-3 position of aglycone ring according to the modified Moffat-Pfitzner process with *N,N*-dimethylaminopropyl-ethyl-carbodiimide in the presence of dimethylsulfoxide and pyridinium trifluoroacetate as a catalyst, in an inert organic solvent, preferably in methylene chloride, at a temperature from 10°C to room temperature, yielding 3-decladinosyl-3-oxo-6-*O*-methyl-9a-aza-9a-homoerythromycin A 2'-*O*-acetate or 3-decladinosyl-3-oxo-6-*O*-methyl-8a-aza-8a-homoerythromycin A 2'-*O*-acetate of the general formula (I), wherein A represents NH group and B at the same time represents C=O group, or A represents C=O group and B at the same time represents NH group, R<sup>1</sup> and R<sup>2</sup> together represent ketone and R<sup>3</sup> represents acetyl group.

Step 6:

3-decladinosyl-3-oxo-6-*O*-methyl-9a-aza-9a-homoerythromycin A 2'-*O*-acetate or 3-decladinosyl-3-oxo-6-*O*-methyl-8a-aza-8a-homoerythromycin A 2'-*O*-acetate of Step 5 of the general formula (I), wherein A, B, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the above-mentioned meanings, are then subjected to solvolysis in lower alcohols, preferably in methanol, at a temperature from room temperature to the reflux temperature of the solvent, yielding 3-decladinosyl-3-oxo-6-*O*-methyl-9a-aza-9a-homoerythromycin A or 3-decladinosyl-3-oxo-6-*O*-methyl-8a-aza-8a-homoerythromycin A of the general formula (I), wherein A represents NH group and B at the same time represents C=O

group, or A represents C=O group and B at the same time represent NH group, R<sup>1</sup> and R<sup>2</sup> together represent ketone and R<sup>3</sup> represents hydrogen.

Pharmaceutically acceptable addition salts, which are also an object of the present invention are obtained by the reaction of new compounds from the class of 6-O-methyl-8a-aza-8a-homoerythromycin A and 6-O-methyl-9a-aza-9a-homoerythromycin A of the general formula (I), wherein A, B, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the above-mentioned meanings, with at least equimolar amount of an appropriate inorganic or organic acid such as hydrochloric, hydroiodic, sulfuric, phosphoric, acetic, propionic, trifluoroacetic, maleic, citric, stearic, succinic, ethylsuccinic, methanesulfonic, benzenesulfonic, p-toluenesulfonic and laurylsulfonic acids in a solvent inert to the reaction. The addition salts are isolated by filtration if they are insoluble in a solvent inert to the reaction, by precipitation with a non-solvent or by evaporation of the solvent, mostly by method of lyophilization.

Antibacterial *in vitro* action of the new compounds of the general formula (I), wherein A, B, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the above-mentioned meanings, and of their pharmaceutically acceptable addition salts with inorganic or organic acids was determined on a series of standard test microorganisms and clinical isolates by microdilution process according to the protocol NCCLS (The National Committee for Clinical Laboratory Standards, Document M7-A2, Vol. 10, No. 8, 1990 and Document M11-A2, Vol. 10, 15, 1991). The control of the laboratory process was performed by means of control strain *Staphylococcus aureus* ATTC 29213 (The American Type Culture Collection) according to protocol NCCLS (Document M7-A2, Table 3, M100-S4).

The antibacterial *in vitro* action on a series of standard test microorganisms for 6-O-methyl-8a-aza-8a-homoerythromycin A from Example 3 in comparison with azithromycin, erythromycin and clarithromycin is represented in Table 1.

Table 1: Antibacterial *in vitro* action (MIC, mg/l) of 6-*O*-methyl-8a-aza-8a-homo-erythromycin A (Example 3) in comparison with azithromycin (Az), erythromycin (Er) and clarithromycin (Cl)

Test microorganism	Az	Er	Cl	Example 3
<i>Listeria monocytogenes</i> ATCC 7644	<0.125	<0.125	<0.125	<0.125
<i>Staphylococcus aureus</i> ATCC 25923	0.5	0.25	0.5	0.5
<i>Staphylococcus epidermidis</i> ATCC 12228	1.0	0.25	0.25	0.5
<i>Enterococcus faecalis</i> ATCC 35550	0.5	1.0	0.25	1.0
<i>Streptococcus pneumoniae</i> ATCC 6305	<0.125	<0.125	<0.125	<0.125
<i>Streptococcus pyogenes</i> ATCC 19615	<0.125	<0.125	<0.125	<0.125
<i>Clostridium perfringens</i> ATCC 13124	0.125	0.5	0.125	0.25
<i>Moraxella catarrhalis</i> ATCC 25238	<0.125	<0.125	<0.125	<0.125
<i>Campylobacter fetus</i> ATCC 19438	<0.125	<0.125	<0.125	<0.125
<i>Campylobacter jejuni</i> ATCC 33291	<0.125	<0.125	<0.125	<0.125
<i>Citrobacter freundii</i> ATCC 8090	4.0	64.0	64.0	16.0
<i>Escherichia coli</i> ATCC 25922	2.0	32.0	32.0	8.0
<i>Proteus mirabilis</i> ATCC 12453	64.0	>128.0	128.0	32.0
<i>Proteus mirabilis</i> ATCC 43071	64.0	>128.0	>128.0	32.0
<i>Salmonella choleraesuis</i> ATCC 13076	2.0	64.0	32.0	8.0
<i>Shigella flexneri</i> ATCC 12022	1.0	32.0	32.0	4.0
<i>Yersinia enterocolitica</i> ATCC 9610	1.0	16.0	16.0	4.0
<i>Haemophilus influenzae</i> ATCC 49247	0.5	2.0	4.0	1.0
<i>Haemophilus influenzae</i> ATCC 49766	1.0	4.0	8.0	1.0
<i>Pseudomonas aeruginosa</i> ATCC 25619	64.0	>128.0	>128.0	32.0



The process is illustrated by the following Examples, which do not limit the scope of the invention in any way.

### Example 1

#### Preparation of 6-*O*-methylethromycin A 9(*E*)- and 9(*Z*)-oxime

##### Method A

6-*O*-methylethromycin A (2.0 g, 0.003 mole) in methanol (100 ml) was heated to the reflux temperature, hydroxylamine hydrochloride (2.0 g, 0.03 mole) and sodium carbonate (0.2 g, 0.002 mole) were added and it was heated under reflux while stirring for 3 hours. Then repeatedly the same amounts of hydroxylamine hydrochloride and sodium carbonate were added and it was heated under reflux for further 6 hours. Methanol was evaporated at reduced pressure and then water (200 ml) and chloroform (100 ml) were added, pH was adjusted to 9.8, the layers were separated and the aqueous layer was extracted twice more with chloroform. The combined organic extracts were dried over potassium carbonate, filtered and evaporated at reduced pressure, yielding 2.0 g of a mixture of the title products. By chromatography on silica gel column using the system methylene chloride-methanol-conc. ammonium hydroxide 90:9:1.5, 0.63 g of chromatographically homogeneous 6-*O*-methylethromycin A 9(*E*)-oxime with R<sub>f</sub> 0.446 and 0.61 g of chromatographically homogeneous 6-*O*-methylethromycin A 9(*Z*)-oxime with R<sub>f</sub> 0.355 were obtained.

9(*E*)-oxime:

R<sub>f</sub> 0.418, ethylacetate-(n-hexane)-diethylamine, 100:100:20

IR (KBr) cm<sup>-1</sup>: 3449, 2974, 2939, 2832, 2788, 1735, 1638, 1459, 1379, 1348, 1169, 1112, 1054, 1012, 957, 835, 755.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 5.11 (H-13), 4.95 (H-1"), 4.45 (H-1'), 4.03 (H-5"), 3.77 (H-8), 3.76 ((H-3), 3.75 (H-11), 3.66 (H-5), 3.48 (H-5'), 3.33 (3"-OCH<sub>3</sub>), 3.24 (H-2"), 3.10 (6-OCH<sub>3</sub>), 3.03 (H-4"), 2.89 (H-2), 2.57 (H-10), 2.45 (H-3'), 2.37 (H-2"a), 2.31 /3'-N(CH<sub>3</sub>)<sub>2</sub>/, 1.93 (H-4), 1.93 (H-14a), 1.68 (H-4'a), 1.58 (H-2"b), 1.53 (H-7a), 1.48 (6-CH<sub>3</sub>), 1.46 (H-14b), 1.31 (5"-CH<sub>3</sub>), 1.25 (3"-CH<sub>3</sub>), 1.23 (5'-CH<sub>3</sub>), 1.20 (2-CH<sub>3</sub>), 1.13 (10-CH<sub>3</sub>), 1.13 (12-CH<sub>3</sub>), 1.08 (4-CH<sub>3</sub>), 1.00 (8-CH<sub>3</sub>), 0.86 (15-CH<sub>3</sub>).



$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 175.5 (C-1), 169.2 (C-9), 102.5 (C-1'), 95.7 (C-1''), 80.2 (C-5), 78.4 (C-6), 78.0 (C-3), 77.8 (C-4''), 76.5 (C-13), 73.8 (C-12), 72.4 (C-3''), 71.1 (C-2'), 70.0 (C-11), 68.2 (C-5'), 65.2 (C-5''), 64.9 (C-3'), 50.8 (6- $\text{OCH}_3$ ), 49.1 (3''- $\text{OCH}_3$ ), 44.7 (C-2), 40.1 /3'- $\text{N}(\text{CH}_3)_2$ /, 38.7 (C-4), 37.0 (C-7), 34.6 (C-2''), 32.3 (C-10), 29.4 (C-4'), 24.9 (C-8), 21.1 (5'- $\text{CH}_3$ ), 21.0 (3''- $\text{CH}_3$ ), 20.8 (C-14), 19.6 (6- $\text{CH}_3$ ), 18.3 (5''- $\text{CH}_3$ ), 18.2 (8- $\text{CH}_3$ ), 15.7 (12- $\text{CH}_3$ ), 15.6 (2- $\text{CH}_3$ ), 14.6 (10- $\text{CH}_3$ ), 10.2 (15- $\text{CH}_3$ ), 8.8 (4- $\text{CH}_3$ ).

9(Z)-oxime:

Rf 0.300, ethylacetate-(n-hexane)-diethylamine, 100:100:20

IR (KBr)  $\text{cm}^{-1}$ : 3433, 2973, 2939, 2832, 1733, 1638, 1459, 1379, 1348, 1286, 1169, 1114, 1054, 1011, 958, 892, 755.

$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 5.07 (H-13), 4.93 (H-1''), 4.43 (H-1'), 4.03 (H-5''), 3.98 (H-11), 3.77 (H-3), 3.62 (H-5), 3.48 (H-5'), 3.33 (3''- $\text{OCH}_3$ ), 3.21 (H-2'), 3.09 (6- $\text{OCH}_3$ ), 3.06 (H-4''), 2.88 (H-2), 2.74 (H-8), 2.65 (H-10), 2.45 (H-3'), 2.36 (H-2''a), 2.30/3'- $\text{N}(\text{CH}_3)_2$ /, 1.96 (H-4), 1.94 (H-14a), 1.76 (H-14b), 1.67 (H-4'a), 1.59 (H-2''b), 1.58 (H-7a), 1.47 (H-7b), 1.38 (6- $\text{CH}_3$ ), 1.32 (10- $\text{CH}_3$ ), 1.31 (5''- $\text{CH}_3$ ), 1.25 (3''- $\text{CH}_3$ ), 1.24 (5'- $\text{CH}_3$ ), 1.19 (2- $\text{CH}_3$ ), 1.14 (12- $\text{CH}_3$ ), 1.07 (4- $\text{CH}_3$ ), 1.06 (8- $\text{CH}_3$ ), 0.84 (15- $\text{CH}_3$ ).

$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 176.0 (C-1), 167.4 (C-9), 102.7 (C-1'), 96.0 (C-1''), 80.4 (C-5), 78.7 (C-6), 78.5 (C-3), 77.8 (C-4''), 76.9 (C-13), 74.7 (C-12), 72.6 (C-3''), 70.9 (C-2'), 70.3 (C-11), 68.4 (C-5'), 65.5 (C-5''), 65.3 (C-3'), 50.0 (6- $\text{OCH}_3$ ), 49.3 (3''- $\text{OCH}_3$ ), 45.0 (C-2), 41.0 /3'- $\text{N}(\text{CH}_3)_2$ /, 38.9 (C-4), 37.0 (C-7), 35.6 (C-8), 34.7 (C-2''), 34.1 (C-10), 28.9 (C-4'), 21.3 (3''- $\text{CH}_3$ ), 21.2 (5'- $\text{CH}_3$ ), 21.1 (C-14), 19.7 (6- $\text{CH}_3$ ), 19.6 (8- $\text{CH}_3$ ), 18.5 (5''- $\text{CH}_3$ ), 16.4 (12- $\text{CH}_3$ ), 15.7 (2- $\text{CH}_3$ ), 10.7 (10- $\text{CH}_3$ ), 10.4 (15- $\text{CH}_3$ ), 9.8 (15- $\text{CH}_3$ ).

#### Method B

6-O-methylerythromycin A (10.8 g, 0.014 mole) in methanol (800 ml) was heated to the reflux temperature, then hydroxylamine hydrochloride (27.0 g, 0.388 mole) and anhydrous sodium acetate (15.0 g, 0.183 mole) were added to the reaction solution in

4 portions within 10 hours and it was heated under reflux while stirring for further 8 hours. Methanol was evaporated at reduced pressure, water (1500 ml) and methylene chloride (200 ml) were added, and it was extracted by gradient extraction at pH 5.0 and 9.8. The combined organic extracts at pH 9.8 were dried over potassium carbonate, filtered and evaporated at reduced pressure, yielding 9.5 g of a mixture of the title products. By chromatography on a silica gel column using the system methylene chloride-methanol-conc. ammonium hydroxide 90:9:1.5, chromatographically homogeneous 6-*O*-methylethromycin A 9(*E*)-oxime and 6-*O*-methylethromycin A 9(*Z*)-oxime with physical-chemical constants identical to those of Method A were obtained.

## Example 2

### Beckmann's rearrangement of 6-*O*-methylethromycin A 9(*E*)-oxime

6-*O*-methylethromycin A 9(*E*)-oxime from Example 1 (4.0 g, 0.005 mole) was dissolved in acetone (130 ml) and the solution was cooled to 0-5°C. Subsequently, solutions of *p*-toluenesulfonyl chloride (2.6 g, 0.01 mole) in acetone (40 ml) and sodium hydrogen carbonate (0.830 g, 0.01 mole) in water (130 ml) were dropwise added thereto within 1 hour under stirring. The reaction mixture was stirred at room temperature for 8 hours, acetone was evaporated at reduced pressure and to the aqueous solution chloroform (40 ml) was added, whereupon it was extracted by gradient extraction at pH 5.0 and 9.0. The combined organic extracts at pH 9.0 were evaporated, yielding 2.8 g of 6-*O*-methyl-9a-aza-9a-homoerythromycin A.

R<sub>f</sub> 0.218, ethylacetate-(*n*-hexane)-diethylamine, 100:100:20

IR (KBr) cm<sup>-1</sup>: 3449, 2974, 2939, 2834, 1734, 1706, 1659, 1534, 1459, 1379, 1274, 1169, 1111, 1053, 1011, 958.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 6.12 (9a-CONH), 4.85 (H-1"), 4.68 (H-13), 4.45 (H-1'), 4.21 (H-3), 4.16 (H-10), 4.07 (H-5"), 3.75 (H-5), 3.49 (H-5'), 3.34 (3"-OCH<sub>3</sub>), 3.32 (6-OCH<sub>3</sub>), 3.22 (H-11), 3.20 (H-2'), 3.04 (H-4"), 2.83 (H-2), 2.43 (H-3'), 2.38 (H-2"a), 2.30 /3'-N(CH<sub>3</sub>)<sub>2</sub>/, 2.22 (H-8), 2.07 (H-7a), 1.87 (H-4), 1.87 (H-14a), 1.67 (H-4'a), 1.57 (H-2"b), 1.57 (H-14b), 1.36 (6-CH<sub>3</sub>), 1.33 (H-7b), 1.32 (5"-CH<sub>3</sub>), 1.25

(3"-CH<sub>3</sub>), 1.24 (H-4'b), 1.23 (5'-CH<sub>3</sub>), 1.23 (2-CH<sub>3</sub>), 1.18 (12-CH<sub>3</sub>), 1.16 (10-CH<sub>3</sub>), 1.09 (8-CH<sub>3</sub>), 1.02 (4-CH<sub>3</sub>), 0.89 (15-CH<sub>3</sub>).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ: 179.5 (C-1), 177.3 (C-9), 102.5 (C-1'), 94.9 (C-1"), 79.1 (C-6), 78.5 (C-5), 77.7 (C-4"), 77.7 (C-13), 75.9 (C-3), 73.9 (C-12), 72.5 (C-3"), 72.6 (C-11), 70.7 (C-2'), 68.2 (C-5'), 65.3 (C-5"), 65.1 (C-3'), 51.0 (6-OCH<sub>3</sub>), 49.1 (3"-OCH<sub>3</sub>), 45.1 (C-10), 44.5 (C-2), 41.3 (C-4), 40.0 /3'-N(CH<sub>3</sub>)<sub>2</sub>/, 39.6 (C-7), 35.4 (C-8), 34.4 (C-2"), 28.8 (C-4'), 21.1 (5'-CH<sub>3</sub>), 21.0 (3"-CH<sub>3</sub>), 20.3 (C-14), 20.2 (6-CH<sub>3</sub>), 19.1 (8-CH<sub>3</sub>), 18.1 (5"-CH<sub>3</sub>), 15.9 (12-CH<sub>3</sub>), 14.6 (2-CH<sub>3</sub>), 13.4 (10-CH<sub>3</sub>), 10.7 (15-CH<sub>3</sub>), 8.7 (4-CH<sub>3</sub>).

### Example 3

#### Beckmann's rearrangement of 6-*O*-methylerythromycin A 9(*Z*)-oxime

6-*O*-methylerythromycin A 9(*Z*)-oxime from Example 1 (1.4 g, 0.002 mole) was dissolved in acetone (50 ml) and the solution was cooled to 0-5°C. Subsequently, solutions of p-toluenesulfochloride (1.84 g, 0.014 mole) in acetone (56 ml) and sodium hydrogen carbonate (1.16 g, 0.014 mole) in water (180 ml) were dropwise added thereto within 1 hour under stirring. The reaction mixture was stirred at room temperature for 2 hours, acetone was evaporated at reduced pressure and to the aqueous solution chloroform (70 ml) was added, whereupon it was extracted by gradient extraction at pH 5.0 and 9.0. The combined organic extracts at pH 9.0 were evaporated, yielding 0.80 g of product, which, if appropriate, was purified by chromatography on a silica gel column using the system methylene chloride-methanol-conc. ammonium hydroxide 90:9:1.5, yielding 6-*O*-methyl-8a-aza-8a-homo-erythromycin A with the following physical-chemical constants:

R<sub>f</sub> 0.152, ethylacetate-(n-hexane)-diethylamine, 100:100:20

IR (KBr) cm<sup>-1</sup>: 3442, 2974, 2938, 2833, 1736, 1648, 1535, 1459, 1379, 1284, 1169, 1110, 1055, 1013, 960, 902.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 5.78 (8a-CONH), 5.02 (H-1"), 4.96 (H-13), 4.41 (H-1'), 4.19 (H-8), 4.02 (H-5"), 3.96 (H-3), 3.69 (H-5), 3.51 (H-11), 3.47 (H-5'), 3.32 (3"-

OCH<sub>3</sub>), 3.18 (H-2'), 3.16 (6-OCH<sub>3</sub>), 3.02 (H-4''), 2.68 (H-2), 2.44 (H-3'), 2.35 (H-2''a), 2.29 /3'-N(CH<sub>3</sub>)<sub>2</sub>/, 2.22 (H-10), 1.92 (H-4), 1.91 (H-14a), 1.68 (H-7a), 1.64 (H-4'a), 1.56 (H-2''b), 1.53 (H-7b), 1.47 (H-14b), 1.39 (6-CH<sub>3</sub>), 1.29 (5''-CH<sub>3</sub>), 1.24 (3''-CH<sub>3</sub>), 1.23 (5'-CH<sub>3</sub>), 1.20 (2-CH<sub>3</sub>), 1.18 (10-CH<sub>3</sub>), 1.13 (12-CH<sub>3</sub>), 1.13 (8-CH<sub>3</sub>), 1.07 (4-CH<sub>3</sub>), 0.88 (15-CH<sub>3</sub>).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ: 177.0 (C-1), 174.3 (C-9), 102.9 (C-1'), 95.1 (C-1''), 80.1 (C-5), 78.6 (C-6), 77.9 (C-4''), 77.2 (C-3), 76.7 (C-13), 74.0 (C-12), 72.6 (C-3''), 70.4 (C-2'), 70.1 (C-11), 68.7 (C-5'), 65.4 (C-3'), 65.2 (C-5''), 51.5 (6-OCH<sub>3</sub>), 49.1 (3''-OCH<sub>3</sub>), 45.4 (C-2), 42.6 (C-7), 42.1 (C-4), 41.8 (C-10), 40.6 (C-8), 40.0/3'-N(CH<sub>3</sub>)<sub>2</sub>/, 34.5 (C-2''), 28.3 (C-4'), 23.5 (6-CH<sub>3</sub>), 21.3 (C-14), 21.2 (12-CH<sub>3</sub>), 21.1 (5'-CH<sub>3</sub>), 21.1 (3''-CH<sub>3</sub>), 17.9 (5''-CH<sub>3</sub>), 15.8 (8-CH<sub>3</sub>), 14.8 (2-CH<sub>3</sub>), 10.8 (15-CH<sub>3</sub>), 9.2 (10-CH<sub>3</sub>), 9.1 (4-CH<sub>3</sub>).

#### Example 4

##### 3-decladinosyl-3-oxy-6-O-methyl-9a-aza-9a-homoerythromycin A

The substance from Example 2 (1.5 g, 0.002 mole) was dissolved in 0.25 N hydrochloric acid (40 ml) and it was left to stand for 24 hours at room temperature. To the reaction mixture methylene chloride (30 ml) (pH 1.8) was added and the pH of the mixture was adjusted to 9.0 with conc. ammonia, the layers were separated and the aqueous layer was extracted twice more with methylene chloride (30 ml). The combined organic extracts were washed with a 10% aqueous solution of sodium hydrogen carbonate and water and then evaporated, yielding 1.3 g of a crude product, which, if appropriate, was purified by chromatography on a silica gel column using the system methylene chloride-methanol-conc. ammonium hydroxide 90:9:1.5. From 0.9 g of the crude product there were isolated 0.65 g of chromatographically homogeneous 3-decladinosyl-3-oxy-6-O-methyl-9a-aza-9a-homoerythromycin A with the following physical-chemical constants:

R<sub>f</sub> 0.152, ethylacetate-(n-hexane)-diethylamine, 100:100:20

IR (KBr) cm<sup>-1</sup>: 3438, 2973, 2939, 2879, 2788, 1702, 1658, 1535, 1458, 1373, 1329, 1270, 1173, 1112, 1050, 985, 958, 937.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.16 (9a-CONH), 4.63 (H-13), 3.81 (H-5), 4.45 (H-1'), 4.13 (H-10), 3.78 (H-3), 3.55 (H-5'), 3.30 (6-OCH<sub>3</sub>), 3.25 (H-2'), 3.16 (H-11), 2.66 (H-2), 2.51 (H-3'), 2.39 (H-8), 2.26/3'-N(CH<sub>3</sub>)<sub>2</sub>/, 2.05 (H-4), 1.92 (H-14a), 1.84 (H-7a), 1.68 (H-4'a), 1.57 (H-14b), 1.43 (H-7b), 1.38 (6-CH<sub>3</sub>), 1.33 (2-CH<sub>3</sub>), 1.26 (5'-CH<sub>3</sub>), 1.26 (H-4'b), 1.20 (10-CH<sub>3</sub>), 1.12 (12-CH<sub>3</sub>), 1.11 (8-CH<sub>3</sub>), 1.01 (4-CH<sub>3</sub>), 0.91 (15-CH<sub>3</sub>).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ: 179.3 (C-1), 176.9 (C-9), 106.4 (C-1'), 88.1 (C-5), 79.1 (C-6), 78.7 (C-13), 78.0 (C-3), 73.8 (C-12), 73.9 (C-11), 70.2 (C-2'), 69.7 (C-5'), 65.4 (C-3'), 49.9 (6-OCH<sub>3</sub>), 45.6 (C-10), 43.9 (C-2), 40.8 (C-7), 39.9/3'-N(CH<sub>3</sub>)<sub>2</sub>/, 35.6 (C-4), 32.8 (C-8), 27.8 (C-4'), 20.9 (5'-CH<sub>3</sub>), 20.5 (C-14), 18.3 (6-CH<sub>3</sub>), 17.4 (8-CH<sub>3</sub>), 15.8 (12-CH<sub>3</sub>), 15.9 (2-CH<sub>3</sub>), 14.8 (10-CH<sub>3</sub>), 10.7 (15-CH<sub>3</sub>), 7.5 (4-CH<sub>3</sub>).

### Example 5

#### 3-decladinosyl-3-oxy-6-O-methyl-8a-aza-8a-homoerythromycin A

From the substance (1.5 g, 0.002 mole) of Example 3 there were obtained, according to the process described in Example 4, 1.2 g of a crude product, which, if appropriate, was purified by chromatography on a silica gel column using the system methylene chloride-methanol-conc. ammonium hydroxide 90:9:1.5, yielding chromatographically homogeneous 3-decladinosyl-3-oxy-6-O-methyl-8a-aza-8a-homoerythromycin A with the following physical-chemical constants:

R<sub>f</sub> 0.195, chloroform-methanol-conc. ammonium hydroxide, 6:1:0.1

IR (KBr) cm<sup>-1</sup>: 3438, 2974, 2939, 2788, 1733, 1648, 1535, 1458, 1378, 1263, 1165, 1113, 1075, 1050, 985, 958, 937.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 5.58 (9a-CONH), 5.09 (H-13), 4.38 (H-1'), 3.76 (H-5), 3.92 (H-8), 3.80 (H-3), 2.64 (H-2), 3.54 (H-5'), 3.47 (H-11), 3.25 (H-2'), 2.11 (H-4), 3.12 (6-OCH<sub>3</sub>), 2.48 (H-3'), 2.38 (H-10), 2.25/3'-N(CH<sub>3</sub>)<sub>2</sub>/, 1.94 (H-14a), 2.11 (H-7a), 1.66 (H-4'a), 1.51 (H-7b), 1.50 (H-14b), 1.31 (2-CH<sub>3</sub>), 1.39 (6-CH<sub>3</sub>), 1.12 (4-CH<sub>3</sub>), 1.26 (5'-CH<sub>3</sub>), 1.26 (H-4'b), 1.20 (10-CH<sub>3</sub>), 1.25 (8-CH<sub>3</sub>), 1.13 (12-CH<sub>3</sub>), 0.88 (15-CH<sub>3</sub>).

$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 176.0 (C-1), 174.4 (C-9), 106.1 (C-1'), 89.6 (C-5), 77.3 (C-6), 75.8 (C-13), 78.3 (C-3), 74.3 (C-12), 70.3 (C-11), 69.9 (C-2'), 69.4 (C-5'), 64.9 (C-3'), 49.7 (6- $\text{OCH}_3$ ), 42.1 (C-10), 43.8 (C-2), 41.7 (C-7), 39.9/3'- $\text{N}(\text{CH}_3)_2$ , 35.2 (C-4), 42.4 (C-8), 27.4 (C-4'), 22.3 (5'- $\text{CH}_3$ ), 20.9 (C-14), 20.4 (6- $\text{CH}_3$ ), 20.5 (8- $\text{CH}_3$ ), 15.7 (12- $\text{CH}_3$ ), 15.2 (2- $\text{CH}_3$ ), 9.5 (10- $\text{CH}_3$ ), 10.1 (15- $\text{CH}_3$ ), 7.50 (4- $\text{CH}_3$ ).

### Example 6

#### 3-decladinosyl-3-oxy-6-*O*-methyl-9a-aza-9a-homoerythromycin A 2'-*O*-acetate

To a solution of 3-decladinosyl-3-oxy-6-*O*-methyl-9a-aza-9a-homoerythromycin A (0.750 g, 0.0012 mole) from Example 4 in methylene chloride (25 ml), sodium hydrogen carbonate (0.440 g, 0.0052 mole) and acetic acid anhydride (0.128 ml, 0.0013 mole) were added and it was stirred for 3 hours at room temperature. To the reaction mixture a saturated solution of sodium hydrogen carbonate (30 ml) was added, the layers were separated and the aqueous portion was again extracted with methylene chloride (2 x 20 ml). The combined organic extracts were washed successively with a saturated solution of hydrogen carbonate and water and evaporated, yielding 0.750 g of a crude title product with the following physical-chemical constants:

R<sub>f</sub> 0.403 chloroform-methanol-conc. ammonium hydroxide, 6:1:0.1

IR (KBr)  $\text{cm}^{-1}$ : 3455, 2974, 2940, 2880, 2787, 1748, 1702, 1658, 1540, 1459, 1376, 1239, 1173, 1112, 1061, 986, 958, 937, 904.

### Example 7

#### 3-decladinosyl-3-oxy-6-*O*-methyl-8a-aza-8a-homoerythromycin A 2'-*O*-acetate

To a solution of 3-decladinosyl-3-oxy-6-*O*-methyl-9a-aza-9a-homoerythromycin A (1.5 g, 0.0024 mole) from Example 5 in methylene chloride (40 ml), sodium hydrogen carbonate (0.88 g, 0.01 mole) and acetic acid anhydride (0.250 ml, 0.0025 mole) were added and then, according to the process described in Example 6, there were obtained 1.4 g of the title product with the following physical-chemical constants:



Rf 0.423, chloroform-methanol-conc. ammonium hydroxide, 6:1:0.1

IR (KBr)  $\text{cm}^{-1}$ : 3394, 2972, 2939, 2784, 1736, 1649, 1542, 1459, 1376, 1262, 1165, 1085, 1059, 986, 958, 904.

### Example 8

#### 3-decladinosyl-3-oxo-6-*O*-methyl-9a-aza-9a-homoerythromycin A

To a solution of 3-decladinosyl-3-oxo-6-*O*-methyl-9a-aza-9a-homoerythromycin A 2'-*O*-acetate (0.760 g, 0.0012 mole) from Example 6 in methylene chloride (15 ml), dimethyl sulfoxide (1.27 ml) and *N,N*-dimethylaminopropyl-ethyl-carbodiimid (1.335 g, 0.007 mole) were added. The reaction mixture was cooled to 15°C and then, under stirring and maintaining this temperature, a solution of pyridinium trifluoroacetate (1.37 g, 0.007 mole) in methylene chloride (5 ml) was gradually added dropwise within 30 minutes. The temperature of the reaction mixture was gradually increased to room temperature, the stirring was continued for further 3 hours and then the reaction was ceased by the addition of a saturated solution of NaCl (20 ml) and methylene chloride (20 ml). After alkalizing the reaction mixture to pH 9.5 with 2N NaOH, it was extracted with  $\text{CH}_2\text{Cl}_2$ , the organic extracts were successively washed with a saturated solution of NaCl,  $\text{NaHCO}_3$  and water and then dried over  $\text{K}_2\text{CO}_3$ . After filtration and evaporation of methylene chloride at reduced pressure, 0.800 g of an oily residue were obtained. The oily residue was subjected to the methanolysis (30 ml of methanol) within 24 hours at room temperature. Methanol was evaporated at reduced pressure and the obtained residue (0.625g) was purified by low-pressure chromatography on a silica gel column using the solvent system dichloromethane-methanol-conc. ammonium hydroxide 90:9:0.5. By evaporation of the combined extracts with Rf 0.235, there was obtained a chromatographically homogeneous title product with the following physical-chemical constants:

Rf 0.235, methylene chloride-methanol-conc. ammonium hydroxide 90:9:0.5

IR (KBr)  $\text{cm}^{-1}$ : 3438, 2975, 2939, 2878, 2787, 1744, 1655, 1530, 1458, 1380, 1340, 1304, 1169, 1111, 1075, 1051, 986, 959, 940.



<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 6.63 (9a-CONH), 4.64 (H-13), 4.49 (H-5), 4.41 (H-1'), 4.20 (H-10), 3.90 (H-2), 3.64 (H-5'), 3.34 (H-11), 3.20 (H-2'), 3.07 (6-OCH<sub>3</sub>), 3.02 (H-4), 2.51 (H-3'), 2.30 (H-8), 2.27/3'-N(CH<sub>3</sub>)<sub>2</sub>/, 1.94 (H-14a), 1.94 (H-7a), 1.69 (H-4'a), 1.63 (H-14b), 1.42 (H-7b), 1.40 (2-CH<sub>3</sub>), 1.30 (5'-CH<sub>3</sub>), 1.29 (4-CH<sub>3</sub>), 1.26 (6-CH<sub>3</sub>), 1.25 (H-4'b), 1.22 (12-CH<sub>3</sub>), 1.19 (10-CH<sub>3</sub>), 1.10 (8-CH<sub>3</sub>), 0.91 (15-CH<sub>3</sub>).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 206.8 (C-3), 177.3 (C-1), 173.8 (C-9), 102.6 (C-1'), 79.3 (C-13), 78.4 (C-6), 74.4 (C-5), 73.9 (C-12), 73.1 (C-11), 70.0 (C-2'), 69.1 (C-5'), 65.5 (C-3'), 50.1 (6-OCH<sub>3</sub>), 49.0 (C-2), 46.2 (C-4), 45.3 (C-10), 40.3 (C-7), 40.0/3'-N(CH<sub>3</sub>)<sub>2</sub>/, 34.6 (C-8), 28.3 (C-4'), 21.0 (6-CH<sub>3</sub>), 20.7 (C-14), 19.6 (5'-CH<sub>3</sub>), 18.6 (8-CH<sub>3</sub>), 15.9 (12-CH<sub>3</sub>), 14.1 (2-CH<sub>3</sub>), 13.9 (10-CH<sub>3</sub>), 13.9 (4-CH<sub>3</sub>), 10.7 (15-CH<sub>3</sub>).

### Example 9

#### 3-decladinosyl-3-oxo-6-*O*-methyl-8a-aza-8a-homoerythromycin A

To a solution of 3-decladinosyl-3-oxo-6-*O*-methyl-8a-aza-8a-homoerythromycin A 2'-*O*-acetate (1.4 g, 0.0022 mole) from Example 7 in methylene chloride (30 ml), dimethyl sulfoxide (2.5 ml) and *N,N*-dimethylaminopropyl-ethyl-carbodiimid (2.7 g, 0.014 mole) were added. The reaction mixture was cooled to 15°C and, under stirring and maintaining this temperature, a solution of pyridinium trifluoroacetate (2.7 g, 0.014 mole) in methylene chloride (10 ml) was gradually added dropwise within 30 minutes. According to the process described in Example 8, there were obtained 1.1 g of the title product with the following physical-chemical constants:


IR (KBr) cm<sup>-1</sup>: 3435, 2975, 2939, 2879, 2788, 1746, 1648, 1542, 1458, 1379, 1339, 1302, 1166, 1111, 1076, 1052, 989, 960, 918.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 5.89 (9a-CONH), 5.08 (H-13), 4.42 (H-1'), 4.27 (H-5), 4.03 (H-8), 3.78 (H-2), 3.60 (H-5'), 3.58 (H-11), 3.18 (H-2'), 3.05 (H-4), 2.91 (6-OCH<sub>3</sub>), 2.49 (H-3'), 2.39 (H-10), 2.27/3'-N(CH<sub>3</sub>)<sub>2</sub>/, 1.96 (H-14a), 1.68 (H-7a), 1.68 (H-4'a), 1.50 (H-14b), 1.41 (2-CH<sub>3</sub>), 1.32 (6-CH<sub>3</sub>), 1.30 (4-CH<sub>3</sub>), 1.25 (5'-CH<sub>3</sub>), 1.23 (H-4'b), 1.20 (10-CH<sub>3</sub>), 1.19 (8-CH<sub>3</sub>), 1.17 (12-CH<sub>3</sub>), 0.88 (15-CH<sub>3</sub>).

$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 206.2 (C-3), 170.0 (C-9), 174.6 (C-1), 103.1 (C-1'), 78.2 (C-6), 77.9 (C-5), 77.5 (C-13), 74.1 (C-12), 70.6 (C-11), 70.0 (C-2'), 69.1 (C-5'), 65.5 (C-3'), 50.5 (6- $\text{OCH}_3$ ), 50.4 (C-2), 47.6 (C-4), 42.2 (C-10), 42.1 (C-7), 41.6 (C-8), 39.9/3'- $\text{N}(\text{CH}_3)_2$ /, 28.0 (C-4'), 22.8 (8- $\text{CH}_3$ ), 21.2 (C-14), 20.8 (5'- $\text{CH}_3$ ), 20.1 (6- $\text{CH}_3$ ), 16.1 (12- $\text{CH}_3$ ), 15.4 (2- $\text{CH}_3$ ), 14.4 (4- $\text{CH}_3$ ), 10.5 (15- $\text{CH}_3$ ), 10.1 (10- $\text{CH}_3$ ).

## Claims

1. Compound represented by the general formula (I)




and its pharmaceutically acceptable addition salts with inorganic and organic acids, wherein

A represents NH group and B at the same time represents C=O group, or

A represents C=O group and B at the same time represent NH group,

R<sup>1</sup> represents OH group, L-cladinosyl group of the formula (II)




or together with R<sup>2</sup> represents ketone,

R<sup>2</sup> represents hydrogen or together with R<sup>1</sup> represents ketone,

R<sup>3</sup> represents hydrogen or C<sub>1</sub>-C<sub>4</sub>alkanoyl group.


2. Compound according to claim 1, characterized in that A represents NH group, B represents C=O group, R<sup>1</sup> represents L-cladinosyl group of the formula (II), R<sup>2</sup> and R<sup>3</sup> are the same and represent hydrogen.
3. Compound according to claim 1, characterized in that A represents C=O group, B represents NH group, R<sup>1</sup> represents L-cladinosyl group of the formula (II) and R<sup>2</sup> and R<sup>3</sup> are the same and represent hydrogen.
4. Compound according to claim 1, characterized in that A represents NH group, B represents C=O group, R<sup>1</sup> represents OH group and R<sup>2</sup> and R<sup>3</sup> are the same and represent hydrogen.
5. Compound according to claim 1, characterized in that A represents C=O group, B represents NH group, R<sup>1</sup> represents OH group and R<sup>2</sup> and R<sup>3</sup> are the same and represent hydrogen.
6. Compound according to claim 1, characterized in that A represents NH group, B represents C=O group, R<sup>1</sup> represents OH group, R<sup>2</sup> is hydrogen and R<sup>3</sup> represents C<sub>1</sub>-C<sub>4</sub> alkanoyl group.
7. Compound according to claim 6, characterized in that R<sup>3</sup> represents acetyl group.
8. Compound according to claim 1, characterized in that A represents C=O group, B represents NH group, R<sup>1</sup> represents OH group, R<sup>2</sup> is hydrogen and R<sup>3</sup> represents C<sub>1</sub>-C<sub>4</sub> alkanoyl group.
9. Compound according to claim 8, characterized in that R<sup>3</sup> represents acetyl group.
10. Compound according to claim 1, characterized in that A represents NH group, B represents C=O group, R<sup>1</sup> and R<sup>2</sup> together represent ketone and R<sup>3</sup> is hydrogen.

11. Compound according to claim 1, characterized in that A represents C=O group, B represents NH group,  $R^1$  and  $R^2$  together represent ketone and  $R^3$  is hydrogen.
12. Process for the preparation of a compound of the general formula (I)




and its pharmaceutically acceptable addition salts with inorganic and organic acids, wherein

A represents NH group and B at the same time represents C=O group, or  
 A represents C=O group and B at the same time represents NH group,  
 $R^1$  represents OH group, L-cladinosyl group of the formula (II)




or together with  $R^2$  represents ketone,  
 $R^2$  represents hydrogen or together with  $R^1$  represents ketone,  
 $R^3$  represents hydrogen or C<sub>1</sub>-C<sub>4</sub>alkanoyl group,


characterized in that 6-*O*-methylethromycin A of the formula (III)



is subjected to a reaction with hydroxylamine hydrochloride in the presence of appropriate inorganic or organic bases, yielding a mixture of 6-*O*-methylethromycin A 9(E)- and 9(Z)-oximes of the formula (IV)




which, if appropriate, is subjected to separation on a silica gel column using the system methylene chloride-methanol-conc. ammonium hydroxide 90:9:1.5, yielding chromatographically homogeneous 6-*O*-methyl-erythromycin A 9(*E*)-oxime with R<sub>f</sub> 0.446 of the formula (IVa)



and chromatographically homogeneous 6-*O*-methylerythromycin A 9(*Z*)-oxime with R<sub>f</sub> 0.355 of the formula (IVb)





and then to the reaction of Beckmann's rearrangement with arylsulfonyl halides, preferably with p-toluenesulfonyl chloride, in the presence of inorganic bases, preferably sodium hydrogen carbonate, in a solvent or solvent mixture inert to the reaction, preferably in a mixture of acetone-water, yielding in the case of 6-*O*-methylerythromycin A 9(*E*)-oxime of the formula (IVa) a compound of the general formula (I), wherein A represents NH group, B represents C=O group, R<sup>1</sup> represents L-cladinosyl group of the formula (II) and R<sup>2</sup> and R<sup>3</sup> are the same and represent hydrogen, or in the case of 6-*O*-methylerythromycin A 9(*Z*)-oxime of the formula (IVb) a compound of the general formula (I), wherein A represents C=O group, B represents NH group, R<sup>1</sup> represents L-cladinosyl group and R<sup>2</sup> and R<sup>3</sup> are the same and represent hydrogen,

which is then subjected to the action of diluted inorganic acids, preferably 0.25 N hydrochloric acid, at a room temperature, yielding a compound of the general formula (I), wherein A represents NH group and B at the same time represents C=O group, or A represents C=O group and B at the same time represents NH group, R<sup>1</sup> represents OH group and R<sup>2</sup> and R<sup>3</sup> are the same and represent hydrogen,

which is then subjected to the reaction of selective acylation with anhydrides of carboxylic acids with up to 4 carbon atoms, preferably with acetic acid anhydride in an inert organic solvent, preferably in methylene chloride, yielding a compound of general formula (I), wherein A represents NH group and B at the same time represents C=O group, or A represents C=O group and B at the same time represents NH group, R<sup>1</sup> is OH group, R<sup>2</sup> is hydrogen and R<sup>3</sup> is acetyl,

which is then subjected to oxidation with diimides, preferably with *N,N*-dimethylaminopropyl-ethyl-carbodiimide in the presence of dimethylsulfoxide and pyridinium trifluoroacetate as a catalyst in an inert organic solvent, preferably in methylene chloride, at a temperature from 10°C to room temperature, yielding a compound of the general formula (I), wherein A represents NH group and B at the same time represents C=O group, or A represents C=O group and B at the same time represents NH group, R<sup>1</sup> together with R<sup>2</sup> represents ketone and R<sup>3</sup> is acetyl group,

which is then subjected to the reaction of deacylation at 2'-position by solvolysis in lower alcohols, preferably in methanol at room temperature, yielding a compound of the general formula (I), wherein A represents NH group and B at the same time represents C=O group, or A represents C=O group and B at the same time represents NH group, R<sup>1</sup> together with R<sup>2</sup> represent ketone and R<sup>3</sup> is hydrogen,

which, if appropriate, is then subjected to the reaction with inorganic or organic acids, yielding their pharmaceutically acceptable addition salts.

13. Pharmaceutical composition useful for treating bacterial infections in humans and animals, which contains antibacterially effective amounts of a compound of the general formula (I) or of its pharmaceutically acceptable addition salts according to claim 1 in combination with a pharmaceutically acceptable carrier.

14. Method for treating bacterial infections in humans and animals, which comprises administering to a human or an animal, as required, antibacterially effective amounts of a compound of the general formula (I) or of its pharmaceutically acceptable

addition salts according to claim 1 in combination with a pharmaceutically acceptable carrier.

# INTERNATIONAL SEARCH REPORT

Int l Application No

PCT/HR 99/00004

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07H17/08 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 549 040 A (MERCK & CO INC) 30 June 1993 (1993-06-30) example 4	1-14
Y	EP 0 507 595 A (MERCK & CO INC) 7 October 1992 (1992-10-07) abstract	1-14
Y	EP 0 596 802 A (ROUSSEL UCLAF) 11 May 1994 (1994-05-11) abstract	1-14
Y	EP 0 422 843 A (TAISHO PHARMA CO LTD) 17 April 1991 (1991-04-17) claim 1	1-14
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 August 1999

Date of mailing of the international search report

27/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Scott, J

# INTERNATIONAL SEARCH REPORT

Int ernational Application No

PCT/HR '99/00004

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>S.T.WADDELL ET AL.: "Synthesis and Antibacterial Activity of O-methyl Derivatives of Azalide Antibiotics : II. 6-OMe Derivatives via Clarithromycin." BIOORGANIC MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 11, June 1998 (1998-06), pages 1321-1326, XP004137197  page 1324, compound 17</p>	<p>1,2, 12-14</p>

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/HR 99/00004

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 14  
is directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/HR 99/00004

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0549040 A	30-06-1993	CA 2083762 A	21-06-1993
		JP 5255374 A	05-10-1993
		JP 6092434 B	16-11-1994
EP 0507595 A	07-10-1992	US 5202434 A	13-04-1993
		CA 2064985 A	06-10-1992
		JP 5239086 A	17-09-1993
EP 0596802 A	11-05-1994	FR 2697523 A	06-05-1994
		FR 2707088 A	06-01-1995
		AT 135706 T	15-04-1996
		AU 670329 B	11-07-1996
		AU 5047793 A	19-05-1994
		BR 9304481 A	21-06-1994
		CA 2102457 A	06-05-1994
		CN 1090581 A, B	10-08-1994
		DE 69301897 D	25-04-1996
		DK 596802 T	03-06-1996
		ES 2085130 T	16-05-1996
		GR 3019385 T	30-06-1996
		HU 66446 A	28-11-1994
		JP 6220082 A	09-08-1994
		US 5527780 A	18-06-1996
		US 5614614 A	25-03-1997
EP 0422843 A	17-04-1991	AT 118503 T	15-03-1995
		CA 2027074 A	08-04-1991
		DE 69016912 D	23-03-1995
		DE 69016912 T	06-07-1995
		DK 422843 T	03-04-1995
		ES 2071036 T	16-06-1995
		JP 3204893 A	06-09-1991
		US 5302705 A	12-04-1994